Last reviewed · How we verify
Vectical Ointment
Vectical is a topical vitamin D3 analog that binds to vitamin D receptors in skin cells to promote differentiation and reduce excessive proliferation in psoriasis.
Vectical is a topical vitamin D3 analog that binds to vitamin D receptors in skin cells to promote differentiation and reduce excessive proliferation in psoriasis. Used for Plaque psoriasis (topical treatment).
At a glance
| Generic name | Vectical Ointment |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Vitamin D3 analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcitriol, the active ingredient in Vectical, is a potent vitamin D3 analog that activates the vitamin D receptor (VDR) on keratinocytes and immune cells in the skin. This activation promotes normal cell differentiation, reduces inflammatory cytokine production, and suppresses the abnormal keratinocyte proliferation characteristic of psoriasis. The topical formulation delivers the drug directly to affected skin areas while minimizing systemic absorption.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Skin irritation at application site
- Hypercalcemia (with excessive use)
- Pruritus
Key clinical trials
- Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis (PHASE3)
- Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis (PHASE4)
- A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis (PHASE2)
- Plaque Psoriasis Study in Pediatric Subjects (PHASE4)
- PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (PHASE4)
- Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (PHASE4)
- Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis (PHASE3)
- Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vectical Ointment CI brief — competitive landscape report
- Vectical Ointment updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI